| 产品详细信息Description: The BTLA antibody reacts with mouse BTLA, B and T lymphocyte attenuator from both BALB/c and C57Bl/6 strains. BTLA is expressed by peripheral lymphocytes, splenic macrophages, developing B cells in the bone marrow and developing T cells in thymus and mature, but not immature bone marrow-derived dendritic cells. BTLA is implicated as a negative regulator of the activation and/or function of various hemopoietic cell types. It is reported that BTLA binds to B7-H4, but further studies are needed to confirm this interaction.Note: The anti-mouse BTLA monoclonal antibody 6F7 is reported to stain CD4+ and CD8+ single-positive (SP) thymocytes (Hurchla et al). However, other anti-mouse BTLA clones generated simultaneously with 6F7 (8F4, 3F9.D12, 6G3 and 6H6) do not stain SP thymocytes. It is not understood why there is a discrepancy in thymocyte staining. However, in staining of splenocytes and bone marrow cells, clones 8F4, 3F9.D12, 6G3 and 6H6 stain similar populations to 6F7.Applications Reported: This 8F4 antibody has been reported for use in flow cytometric analysis.Applications Tested: This 8F4 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.125 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser.Filtration: 0.2 µm post-manufacturing filtered.靶标信息BTLA or B and T-lymphocyte attenuator is a member of the co-inhibitory receptors of the CD28 superfamily. BTLA is a lymphocyte inhibitory receptor which inhibits lymphocytes during immunes responses. BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. It remains expressed on Th1 cells, but not Th2 cells. BTLA is a unique co-receptor that interacts with the tumor necrosis factor receptor superfamily member herpesvirus entry mediator (HVEM). This interation is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response. |
| 1.International journal of clinical and experimental pathologyBTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis."17-5956 was used in Immunofluorescence to determine that BTLA may be involved in the control of inflammatory responses through increasing Foxp3 expression in DSS-induced colitis."AuthorsZhang HX,Zhu B,Fu XX,Zeng JC,Zhang JA,Wang WD,Kong B,Xiang WY,Zhong J,Wang CY,Zheng XB,Xu JF2.OncoimmunologyCompensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer."17-5956 was used in Flow cytometry/Cell sorting to provide a basis for combinatorial checkpoint blockade in clinical intervention for ovarian cancer."AuthorsHuang RY,Francois A,McGray AR,Miliotto A,Odunsi K3.International journal of clinical and experimental pathologyBTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis."17-5956 was used in Immunofluorescence to determine that BTLA may be involved in the control of inflammatory responses through increasing Foxp3 expression in DSS-induced colitis."AuthorsZhang HX,Zhu B,Fu XX,Zeng JC,Zhang JA,Wang WD,Kong B,Xiang WY,Zhong J,Wang CY,Zheng XB,Xu JF |
QQ:1749072012